Africa's Path to Vaccine Self-Sufficiency: New South African Plant Offers Hope Amidst Challenges

The African Development Bank (AfDB) has signed an agreement to support the construction of a new vaccine manufacturing facility in South Africa. This marks the latest step for the continent in its journey to reduce reliance on imported vaccines. Amidst ongoing outbreaks of diseases, enhancing self-sufficiency in the health sector is both an urgent requirement and a difficult challenge for Africa. The project to build a vaccine manufacturing facility in South Africa signifies a notable shift in the African health sector, moving from a focus on imports to prioritizing the development of infrastructure and technology transfer to boost the region's vaccine production capacity. According to the plan, once operational, the facility will be the first in Africa to produce oral cholera vaccines, with subsequent expansion to include vaccines for polio, pneumonia, and meningitis. Through this project, the production capacity of the South African Institute for Biological and Vaccine (Biovac) is projected to reach 500 million doses per year by 2028. This initiative follows a series of efforts implemented in various African countries recently, such as Rwanda, Senegal, and Egypt. AfDB Vice President Solomon Quaynor affirmed that the goal is not only to expand vaccine production capacity but also to achieve long-term development objectives, ensuring "health sovereignty" and enhancing the ability to respond to future health emergencies. Analysts suggest that this is a necessary step to fill existing "gaps" in the region's health system. Africa accounts for over 18% of the global population and is frequently a "hotspot" for disease outbreaks. However, only about 1% of the vaccines used across the continent are produced domestically. Furthermore, manufacturing facilities are not evenly distributed across the region, primarily concentrating in a few countries, making vaccine supply self-sufficiency a persistent challenge. This weakness was clearly exposed during the COVID-19 pandemic, when the world witnessed an "uneven race" between developed and developing countries, especially in Africa, for vaccine access. At the peak of the outbreak, while wealthy nations—home to most major pharmaceutical companies—quickly secured necessary vaccine supplies, even experiencing surpluses, Africa could only access them sporadically. The vast disparity in vaccination rates led the World Health Organization (WHO) to lament that Africa was "left behind" due to delays and shortages in vaccine supply. This reality not only reflects global inequality in vaccine distribution but also exposes serious "vulnerabilities" in Africa's health system. It is not impossible that the world will face other pandemics, especially as factors increasing the risk of outbreaks, such as natural disasters, conflicts, and humanitarian crises, are occurring simultaneously with increasing frequency and intensity. The "wake-up call" from the COVID-19 pandemic shows that a lack of proactive health supply has caused significant difficulties for Africa in responding to crises and may continue to put it in a passive position whenever an epidemic emerges. To prevent a repeat of past scenarios, enhancing vaccine production capacity has been a priority on the region's agenda in recent years. The African Union (AU) has set a target to self-supply 60% of the continent's vaccine needs by 2040, aiming to end excessive dependence on external supplies. In recent times, Africa has made certain progress on its path toward self-sufficiency in production and ensuring access to essential vaccines for its people. However, the road ahead is fraught with challenges. Analysts believe the question now is not whether the continent can build vaccine manufacturing plants, but rather how to maintain their operation and improve their efficiency. A high-quality workforce, a stable consumer market, long-term investment capital, and production technology are difficult problems that regional leaders need to find solutions for soon to unlock Africa's vaccine self-sufficiency potential. Information Source: Nhan Dan